DYNDyne Therapeutics, Inc.

1. Sep 29, 2026On September 29, 2026, the Company issued a press release and presentation announcing additional one-year clinical data from the ACHIEVE trial evaluating z-basivarsen in individuals with DM1.Regulation FD disclosure · Form 8-K
2. Jul 29, 2026Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
3. Jul 22, 2026On July 21, 2026, Dyne Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the …Material agreement entered · Form 8-K
4. Jul 20, 2026On July 20, 2026, Dyne Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its biologics license application (“BLA”) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy …Other event · Form 8-K
5. Jun 22, 2026On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and …Director or officer change · Form 8-K
6. Jun 17, 2026On June 16, 2026 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the Second Amendment (the “Second Amendment”) to its Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial …Material agreement entered · Form 8-K
7. Jun 3, 2026On June 3, 2026, the Company issued a press release announcing full enrollment of the REC of its Phase 1/2 ACHIEVE trial of z-basivarsen in individuals with DM1 with 71 participants.Regulation FD disclosure · Form 8-K
8. May 11, 2026Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
9. Mar 2, 2026Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights.Earnings release · press release
10. Dec 23, 2025On December 22, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders and …Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.